{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:07:05Z","timestamp":1789160825931,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2023YFE0206500"],"award-info":[{"award-number":["2023YFE0206500"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2023YFC2606500"],"award-info":[{"award-number":["2023YFC2606500"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutical Science Advances"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.pscia.2026.100147","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:36:11Z","timestamp":1788503771000},"page":"100147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The substrate envelope strategy: Structural basis for resistance mitigation in antiviral drug design"],"prefix":"10.1016","volume":"4","author":[{"given":"Qiaojie","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edeildo F.","family":"Silva-J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pscia.2026.100147_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41579-021-00639-z","article-title":"Infectious disease in an era of global change","volume":"20","author":"Baker","year":"2022","journal-title":"Nat. Rev. Microbiol."},{"issue":"5","key":"10.1016\/j.pscia.2026.100147_bib2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/ICU.0000000000000683","article-title":"Ebola, covid-19, and emerging infectious disease: lessons learned and future preparedness","volume":"31","author":"Bavinger","year":"2020","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"7","key":"10.1016\/j.pscia.2026.100147_bib4","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1039\/D0CS01084G","article-title":"Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses","volume":"50","author":"Ma","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.pscia.2026.100147_bib5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.antiviral.2013.04.010","article-title":"Molecular virology of chronic hepatitis b and C: parallels, contrasts and impact on drug development and treatment outcome","volume":"99","author":"Delaney","year":"2013","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.pscia.2026.100147_bib6","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.09.020421","article-title":"Global mortality associated with seasonal influenza epidemics: new burden estimates and predictors from the glamor project","volume":"9","author":"Paget","year":"2019","journal-title":"J. Glob. Health"},{"issue":"9","key":"10.1016\/j.pscia.2026.100147_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","article-title":"Epidemiology and natural history of hcv infection","volume":"10","author":"Hajarizadeh","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.pscia.2026.100147_bib8","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/jac\/dkm082","article-title":"Prevalence and determinants of transmitted antiretroviral drug resistance in hiv-1 infection","volume":"59","author":"Booth","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.pscia.2026.100147_bib9","series-title":"Influenza Virus","author":"Kawaoka","year":"2018"},{"key":"10.1016\/j.pscia.2026.100147_bib10","series-title":"Progress in Drug Research","first-page":"77","article-title":"Virus population dynamics, fitness variations and the control of viral disease: an update","author":"Domingo","year":"2001"},{"issue":"23","key":"10.1016\/j.pscia.2026.100147_bib11","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1007\/s00018-016-2299-6","article-title":"Mechanisms of viral mutation","volume":"73","author":"Sanjuan","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"issue":"7","key":"10.1016\/j.pscia.2026.100147_bib12","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.3390\/ijms25073696","article-title":"Properties and mechanisms of deletions, insertions, and substitutions in the evolutionary history of sars-cov-2","volume":"25","author":"Rogozin","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.pscia.2026.100147_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1042\/EBC20170052","article-title":"Structure-based drug design: aiming for a perfect fit","volume":"61","author":"van Montfort","year":"2017","journal-title":"Essays Biochem."},{"issue":"19\u201320","key":"10.1016\/j.pscia.2026.100147_bib14","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.drudis.2012.06.018","article-title":"Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem","volume":"17","author":"Hao","year":"2012","journal-title":"Drug Discov. Today"},{"issue":"29","key":"10.1016\/j.pscia.2026.100147_bib15","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.2174\/092986709789178019","article-title":"Design strategies of novel nnrtis to overcome drug resistance","volume":"16","author":"Zhan","year":"2009","journal-title":"Curr. Med. Chem."},{"issue":"5","key":"10.1016\/j.pscia.2026.100147_bib16","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1021\/acs.jmedchem.9b01456","article-title":"Designing chimeric molecules for drug discovery by leveraging chemical biology","volume":"63","author":"Borsari","year":"2020","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.pscia.2026.100147_bib17","first-page":"815","article-title":"Multivalent agents: a novel concept and preliminary practice in anti-hiv drug discovery","volume":"20","author":"Song","year":"2013","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/j.pscia.2026.100147_bib18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3201\/eid0404.980402","article-title":"Quasispecies structure and persistence of rna viruses","volume":"4","author":"Domingo","year":"1998","journal-title":"Emerg. Infect. Dis."},{"issue":"2","key":"10.1016\/j.pscia.2026.100147_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/femspd\/ftz021","article-title":"Viral fitness: history and relevance for viral pathogenesis and antiviral interventions","volume":"77","author":"Domingo","year":"2019","journal-title":"Pathog Dis"},{"issue":"3","key":"10.1016\/j.pscia.2026.100147_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0969-2126(02)00720-7","article-title":"Substrate shape determines specificity of recognition for hiv-1 protease: analysis of crystal structures of six substrate complexes","volume":"10","author":"Prabu-Jeyabalan","year":"2002","journal-title":"Structure"},{"issue":"4","key":"10.1016\/j.pscia.2026.100147_bib21","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1128\/AAC.50.4.1518-1521.2006","article-title":"Substrate envelope and drug resistance: crystal structure of ro1 in complex with wild-type human immunodeficiency virus type 1 protease","volume":"50","author":"Prabu-Jeyabalan","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"13","key":"10.1016\/j.pscia.2026.100147_bib22","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1128\/JVI.00377-11","article-title":"Molecular mechanisms of viral and host cell substrate recognition by hepatitis c virus ns3\/4a protease","volume":"85","author":"Romano","year":"2011","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.pscia.2026.100147_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002832","article-title":"The molecular basis of drug resistance against hepatitis c virus ns3\/4a protease inhibitors","volume":"8","author":"Romano","year":"2012","journal-title":"PLoS Pathog."},{"issue":"49","key":"10.1016\/j.pscia.2026.100147_bib24","doi-asserted-by":"crossref","first-page":"20986","DOI":"10.1073\/pnas.1006370107","article-title":"Drug resistance against hcv ns3\/4a inhibitors is defined by the balance of substrate recognition versus inhibitor binding","volume":"107","author":"Romano","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pscia.2026.100147_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101053","article-title":"Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges","volume":"73","author":"Du","year":"2024","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.pscia.2026.100147_bib26","series-title":"Unaids Data 2023","year":"2026"},{"issue":"6","key":"10.1016\/j.pscia.2026.100147_bib27","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2165\/00003495-199958060-00011","article-title":"Indinavir","volume":"58","author":"Plosker","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.pscia.2026.100147_bib28","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1345\/aph.18089","article-title":"Nelfinavir mesylate a protease inhibitor","volume":"33","author":"Pai","year":"1999","journal-title":"Ann. Pharmacother."},{"issue":"6","key":"10.1016\/j.pscia.2026.100147_bib29","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2165\/00003495-199855060-00015","article-title":"Amprenavir","volume":"55","author":"Adkins","year":"1998","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.pscia.2026.100147_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/00003088-199834030-00002","article-title":"Saquinavir","volume":"34","author":"Vella","year":"1998","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.pscia.2026.100147_bib31","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2165\/00003495-200060060-00009","article-title":"Lopinavir","volume":"60","author":"Hurst","year":"2000","journal-title":"Drugs"},{"issue":"16","key":"10.1016\/j.pscia.2026.100147_bib32","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2165\/00003495-200363160-00003","article-title":"Atazanavir","volume":"63","author":"Goldsmith","year":"2003","journal-title":"Drugs"},{"issue":"15","key":"10.1016\/j.pscia.2026.100147_bib33","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2165\/00003495-200363150-00009","article-title":"Tipranavir","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs"},{"issue":"18","key":"10.1016\/j.pscia.2026.100147_bib34","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.2165\/00003495-200767180-00010","article-title":"Darunavir","volume":"67","author":"Fenton","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.pscia.2026.100147_bib35","author":"Prabu-Jeyabalan"},{"issue":"25","key":"10.1016\/j.pscia.2026.100147_bib36","doi-asserted-by":"crossref","first-page":"7342","DOI":"10.1021\/jm060666p","article-title":"Discovery of hiv-1 protease inhibitors with picomolar affinities incorporating n-aryl-oxazolidinone-5-carboxamides as novel p2 ligands","volume":"49","author":"Ali","year":"2006","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.pscia.2026.100147_bib37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1747-0285.2007.00514.x","article-title":"Design of mutation-resistant hiv protease inhibitors with the substrate envelope hypothesis","volume":"69","author":"Chellappan","year":"2007","journal-title":"Chem. Biol. Drug Des."},{"issue":"19","key":"10.1016\/j.pscia.2026.100147_bib38","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1021\/ja076558p","article-title":"Hiv-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants","volume":"130","author":"Altman","year":"2008","journal-title":"JACS"},{"issue":"4","key":"10.1016\/j.pscia.2026.100147_bib39","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jmb.2011.03.053","article-title":"Dynamics of preferential substrate recognition in hiv-1 protease: redefining the substrate envelope","volume":"410","author":"Ozen","year":"2011","journal-title":"J. Mol. Biol."},{"issue":"9","key":"10.1016\/j.pscia.2026.100147_bib40","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.chembiol.2013.07.014","article-title":"Substrate envelope-designed potent hiv-1 protease inhibitors to avoid drug resistance","volume":"20","author":"Nalam","year":"2013","journal-title":"Chem Biol"},{"issue":"17","key":"10.1016\/j.pscia.2026.100147_bib41","doi-asserted-by":"crossref","first-page":"7315","DOI":"10.1021\/acs.jmedchem.7b00596","article-title":"Structure-guided optimization of hiv integrase strand transfer inhibitors","volume":"60","author":"Zhao","year":"2017","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.pscia.2026.100147_bib42","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.addr.2007.04.014","article-title":"Hepatitis c viral life cycle","volume":"59","author":"Suzuki","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.pscia.2026.100147_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.6","article-title":"Hepatitis c virus infection","volume":"3","author":"Manns","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1 Suppl","key":"10.1016\/j.pscia.2026.100147_bib44","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis c virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.pscia.2026.100147_bib45","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/hep.25653","article-title":"Review and management of drug interactions with boceprevir and telaprevir","volume":"55","author":"Kiser","year":"2012","journal-title":"Hepatology"},{"issue":"21","key":"10.1016\/j.pscia.2026.100147_bib46","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in hcv genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.pscia.2026.100147_bib47","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1021\/jm9015526","article-title":"Discovery of vaniprevir (mk-7009), a macrocyclic hepatitis c virus ns3\/4a protease inhibitor","volume":"53","author":"McCauley","year":"2010","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.pscia.2026.100147_bib48","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/apt.14977","article-title":"Review article: novel antivirals for hepatitis c-sofosbuvir\/velpatasvir\/voxilaprevir, glecaprevir\/pibrentasvir","volume":"48","author":"Pearlman","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.pscia.2026.100147_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinme.2025.100522","article-title":"Hepatitis C: current treatments, emerging therapies and tackling health inequities on the path to global elimination","volume":"25","author":"Farooq","year":"2025","journal-title":"Clin. Med."},{"issue":"Pt 4","key":"10.1016\/j.pscia.2026.100147_bib50","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1099\/jgv.0.000009","article-title":"Hepatitis c virus ns5a: enigmatic but still promiscuous 10 years on!","volume":"96","author":"Ross-Thriepland","year":"2015","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.pscia.2026.100147_bib51","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.coph.2016.07.015","article-title":"Hepatitis c virus ns3\/4a protease inhibitors","volume":"30","author":"McCauley","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"issue":"7062","key":"10.1016\/j.pscia.2026.100147_bib52","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nature04193","article-title":"Cardif is an adaptor protein in the rig-i antiviral pathway and is targeted by hepatitis c virus","volume":"437","author":"Meylan","year":"2005","journal-title":"Nature"},{"issue":"49","key":"10.1016\/j.pscia.2026.100147_bib53","doi-asserted-by":"crossref","first-page":"17717","DOI":"10.1073\/pnas.0508531102","article-title":"Hepatitis c virus protease ns3\/4a cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity","volume":"102","author":"Xiao-Dong","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.pscia.2026.100147_bib54","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1038\/s12276-021-00691-y","article-title":"Regulation of antiviral innate immune signaling and viral evasion following viral genome sensing","volume":"53","author":"Chathuranga","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.pscia.2026.100147_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.05.001","article-title":"Type i interferon signaling, regulation and gene stimulation in chronic virus infection","volume":"43","author":"Lukhele","year":"2019","journal-title":"Semin. Immunol."},{"issue":"1","key":"10.1016\/j.pscia.2026.100147_bib56","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/cid\/cir774","article-title":"Boceprevir and telaprevir in the management of hepatitis c virus-infected patients","volume":"54","author":"Butt","year":"2012","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.pscia.2026.100147_bib57","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1021\/cb400100g","article-title":"Evaluating the role of macrocycles in the susceptibility of hepatitis c virus ns3\/4a protease inhibitors to drug resistance","volume":"8","author":"Ali","year":"2013","journal-title":"ACS Chem. Biol."},{"issue":"13","key":"10.1016\/j.pscia.2026.100147_bib58","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1021\/acs.jmedchem.7b00426","article-title":"Hepatitis c virus ns3\/4a protease inhibitors incorporating flexible p2 quinoxalines target drug resistant viral variants","volume":"60","author":"Matthew","year":"2017","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.pscia.2026.100147_bib59","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00172-20","article-title":"Avoiding drug resistance by substrate envelope-guided design: toward potent and robust hcv ns3\/4a protease inhibitors","volume":"11","author":"Matthew","year":"2020","journal-title":"mBio"},{"issue":"16","key":"10.1016\/j.pscia.2026.100147_bib60","doi-asserted-by":"crossref","first-page":"11972","DOI":"10.1021\/acs.jmedchem.1c00554","article-title":"Discovery of quinoxaline-based p1-p3 macrocyclic ns3\/4a protease inhibitors with potent activity against drug-resistant hepatitis c virus variants","volume":"64","author":"Nageswara Rao","year":"2021","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.pscia.2026.100147_bib61","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1055\/s-0036-1584801","article-title":"Human influenza virus infections","volume":"37","author":"Peteranderl","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"issue":"11","key":"10.1016\/j.pscia.2026.100147_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224683","article-title":"Effectiveness of four types of neuraminidase inhibitors approved in Japan for the treatment of influenza","volume":"14","author":"Mawatari","year":"2019","journal-title":"PLoS One"},{"issue":"7107","key":"10.1016\/j.pscia.2026.100147_bib63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature05114","article-title":"The structure of h5n1 Avian influenza neuraminidase suggests new opportunities for drug design","volume":"443","author":"Russell","year":"2006","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.pscia.2026.100147_bib64","doi-asserted-by":"crossref","first-page":"6098","DOI":"10.1021\/acs.jctc.6b00703","article-title":"Molecular basis for differential patterns of drug resistance in influenza n1 and n2 neuraminidase","volume":"12","author":"Prachanronarong","year":"2016","journal-title":"J. Chem. Theor. Comput."},{"issue":"11","key":"10.1016\/j.pscia.2026.100147_bib65","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s40265-020-01350-8","article-title":"Baloxavir marboxil: a review in acute uncomplicated influenza","volume":"80","author":"Shirley","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.pscia.2026.100147_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115035","article-title":"Chemical scaffold recycling: structure-Guided conversion of an hiv integrase inhibitor into a potent influenza virus rna-dependent rna polymerase inhibitor designed to minimize resistance potential","volume":"247","author":"Slavish","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"7836","key":"10.1016\/j.pscia.2026.100147_bib67","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1038\/s41586-020-2951-z","article-title":"Addendum: a pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"588","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pscia.2026.100147_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.616341","article-title":"Recent progress in the drug development targeting sars-cov-2 main protease as treatment for covid-19","volume":"7","author":"Cui","year":"2020","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.pscia.2026.100147_bib69","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1038\/s41467-022-31210-w","article-title":"Defining the substrate envelope of sars-cov-2 main protease to predict and avoid drug resistance","volume":"13","author":"Shaqra","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pscia.2026.100147_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.pscia.2025.100094","article-title":"Conquering viral drug resistance: structural and mechanistic paradigms for antiresistance drug design","volume":"3","author":"Wang","year":"2025","journal-title":"Pharm Sci Adv"},{"issue":"21","key":"10.1016\/j.pscia.2026.100147_bib71","doi-asserted-by":"crossref","first-page":"19057","DOI":"10.1021\/acs.jmedchem.4c01544","article-title":"Pseudosubstrate envelope\"\/free energy perturbation-guided design and mechanistic investigations of benzothiazole hiv capsid modulators with high ligand efficiency","volume":"67","author":"Xu","year":"2024","journal-title":"J. Med. Chem."}],"container-title":["Pharmaceutical Science Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2773216926000413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2773216926000413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:16:20Z","timestamp":1789157780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2773216926000413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":70,"alternative-id":["S2773216926000413"],"URL":"https:\/\/doi.org\/10.1016\/j.pscia.2026.100147","relation":{},"ISSN":["2773-2169"],"issn-type":[{"value":"2773-2169","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The substrate envelope strategy: Structural basis for resistance mitigation in antiviral drug design","name":"articletitle","label":"Article Title"},{"value":"Pharmaceutical Science Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pscia.2026.100147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Shandong University.","name":"copyright","label":"Copyright"}],"article-number":"100147"}}